Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS Interest receivable on interest rate and cross currency swaps

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:InterestReceivableCurrent.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's interest receivable on interest rate and cross currency swaps.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's interest receivable on interest rate and cross currency swaps?
Arcus Biosciences (RCUS) reported interest receivable on interest rate and cross currency swaps of $4M in Q1 2026.
How has Arcus Biosciences's interest receivable on interest rate and cross currency swaps changed year-over-year?
Arcus Biosciences's interest receivable on interest rate and cross currency swaps decreased by 33.3% year-over-year, from $6M to $4M.
What is the long-term trend for Arcus Biosciences's interest receivable on interest rate and cross currency swaps?
Over 5 years (2020 to 2025), Arcus Biosciences's interest receivable on interest rate and cross currency swaps has grown at a 50.4% compound annual growth rate (CAGR), from $649K to $5M.